Skip to content

NYSE · micro · thesis board

ANVS Annovis Bio

Oral translation inhibitor (buntanetap)

View race

Thesis

Editorial summary — not a primary filing

Buntanetap aims at neurodegeneration with oral convenience; late-stage risk remains high.

Next gate

2027-02-01EstimatedPh3 readout

Phase 3 readout

172 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~3 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~274d)100%
Days to gate (172d)63%
Show math

$45M cash ÷ $5M/mo burn ≈ 274 days. Source: curated SEC quarter figures.

Cash $45M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
LLYApprovedokBIIBApprovedokAVXLPh3ok

Risks

  • Cash runway
  • Phase 3 execution
  • Crowded AD field
  • Dilution risk

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05686044as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01